Tweaking the gain on platelet regulation: The tachykinin connection

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 1-7

  Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Endokinin A; Endokinin B; Haemostasis; Neurokinin 1 receptor; Platelet activation; Substance P; Tachykinin; Thrombosis

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTITHROMBOCYTIC AGENT; APREPRITANT; NEUROKININ A; NEUROKININ B; SEROTONIN 2A ANTAGONIST; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR; THROMBOXANE A2; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PARACRINE SIGNALING; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PLATELETS; FEEDBACK, PHYSIOLOGICAL; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; MOLECULAR SEQUENCE DATA; PLATELET ACTIVATION; RECEPTORS, NEUROKININ-1; RECEPTORS, TACHYKININ; TACHYKININS; THROMBOSIS;

EID: 69249248194     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.010     Document Type: Review

References (74)

1. Gibbins J.M. Adhesion receptor signalling and the regulation of thrombus formation. J Cell Sci 117 (2004) 3415-3425
2. Nurden A.T. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 3 (2005) 1773-1782
3. Davi G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
4. von Hundelshausen P., and Weber C. Platelets as immune cells-bridging inflammation and cardiovascular disease. Circ Res 100 (2007) 27-40
5. Massberg S., Brand K., Gruner S., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196 (2002) 887-896
6. Anfossi G., Russo I., and Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 6 (2008) 313-328
7. Wang J.S., Li Y.S., Chen J.C., and Chen Y.W. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arterioscl Thromb Vascul Biol 25 (2005) 454-460
8. Cabeza N., Li Z.Y., Schulz C., et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes 53 (2004) 2117-2121
9. 2+ entry and tyrosine kinase pp60(src) hyperactivity are modulated by hyperglycemia in platelets from patients with non insulin-dependent diabetes mellitus. Arch Biochem Biophys 432 (2004) 261-268
10. Watala C., Golanski J., Pluta J., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicyclic acid (aspirin)-its relation to metabolic control. Thromb Res 113 (2004) 101-113
11. Theilmeier G., Michiels C., Spaepen E., et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 99 (2002) 4486-4493
12. Sobol A.B., and Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 50 (2000) 1-16
13. Trovati M., Mularoni E.M., Burzacca S., Ponziani M.C., and Massucco P. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese niddm patients. Diabetes 44 (1995) 1318-1322
14. Hawkins R.I. Smoking, platelets and thrombosis. Nature 236 (1972) 450-452
15. Hubbard G.P., Stevens J.M., Cicmil M., et al. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components, of the glycoprotein VI signaling pathway. J Thromb Haemost 1 (2003) 1079-1088
16. Hubbard G.P., Wollfram S., Lovegrove J.A., and Gibbins J.M. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2 (2004) 2138-2145
17. Vita J.A. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr 81 (2005) 292S-297S
18. Jackson S.P., and Schoenwaelder S.M. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2 (2003) 775-789
19. Barrett N.E., Holbrook L., Jones S., et al. Future innovations in anti-platelet therapies. Br J Pharmacol 154 (2008) 918-939
20. Ferguson J.J. The role of oral antiplatelet agents in atherothrombotic disease. Am J Cardiovasc Drugs 6 (2006) 149-157
21. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100 (2007) 1261-1275
22. Podrez E.A., Byzova T.V., Febbraio M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13 (2007) 1086-1095
23. Savage B., Saldivar E., and Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84 (1996) 289-297
24. Gibbins J.M., Okuma M., Farndale R., Barnes M., and Watson S.P. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ-chain. FEBS Lett 413 (1997) 255-259
25. Poole A., Gibbins J.M., Turner M., et al. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 16 (1997) 2333-2341
26. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
27. Shattil S.J., and Newman P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104 (2004) 1606-1615
28. Falati S., Edmead C.E., and Poole A.W. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood 94 (1999) 1648-1656
29. Nesbitt W.S., Kulkarni S., Giuliano S., et al. Distinct glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3)-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem 277 (2002) 2965-2972
30. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46 (2006) 277-300
31. Hollopeter G., Jantzen H.-M., Vincent D., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
32. Armstrong R.A. Platelet prostanoid receptors. Pharmacol Ther 72 (1996) 171-191
33. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Exp Opin Invest Drugs 10 (2001) 865-890
34. Radomski M.W., Palmer R.M.J., and Moncada S. Endogenous nitric-oxide inhibits human-platelet adhesion to vascular endothelium. Lancet 2 (1987) 1057-1058
35. Falati S., Patil S., Gross P.L., et al. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107 (2006) 535-541
36. Patil S., Newman D.K., and Newman P.J. PECAM-1 servesas an inhibitory receptor that modulates platelet responses to collagen. Blood 97 (2001) 1727-1732
37. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002) 71-86
38. CAPRIE Steering Committee, a randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
39. Lewis H.D., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial-infarction and death in men with unstable angina-results of a veterans-administration-Cooperative Study. N Engl J Med 309 (1983) 396-403
40. Przyklenk K., Linden M.D., Frelinger A.L., Teegarden B., Adams J., and Michelson A.D. Targeted inhibition of the serotonin 5-HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. Circulation 116 (2007) 206-1206
41. Scarborough R.M., Kleiman N.S., and Phillips D.R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?. Circulation 100 (1999) 437-444
42. Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 113 (2002) 1-6
43. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
44. Heptinstall S., Glenn J.R., May J.A., Storey R.F., and Wilcox R.G. Clopidogrel resistance. Catheter Cardiovasc Interv 63 (2004) 397-398
45. Kroll M.H., Harris T.S., Moake J.L., Handin R.I., and Schafer A.I. Von Willebrand-factor binding to platelet GPIb initiates signals for platelet activation. J Clin Invest 88 (1991) 1568-1573
46. Clemetson J.M., Polgar J., Magnenat E., Wells T.N.C., and Clemetson K.J. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to the FcalphaR and the natural killer receptors. J Biol Chem 274 (1999) 29019-29024
47. Angelillo-Scherrer A., de Frutos P.G., Aparicio C., et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7 (2001) 215-221
48. Andre P., Prasad K.S.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta(3) integrin-dependent mechanism. Nat Med 8 (2002) 247-252
49. Gear A.R., and Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 10 (2003) 335-350
50. Zhu L., Bergmeier W., Wu J., et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci USA 104 (2007) 1621-1626
51. Graham G.J., Stevens J.M., Page N.M., et al. Tachykinins regulate the function of platelets. Blood 104 (2004) 1058-1065
52. Jones S., Tucker K.L., Sage T., et al. Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood 111 (2008) 605-612
53. Flaumenhaft R. Platelets feel your pain. Blood 104 (2004) 913-1913
54. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharmacol Rev 54 (2002) 285-322
55. Grant A.D., Akhtar R., Gerard N.P., and Brain S.D. Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms. J Physiol 543 (2002) 1007-1014
56. Lecci A., Giuliani S., Tramontana M., Carini F., and Maggi C.A. Peripheral actions of tachykinins. Neuropeptides 34 (2000) 303-313
57. Patacchini R., and Maggi C.A. Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 429 (2001) 13-21
58. Zhang Y., Lu L.W., Furlonger C., Wu G.E., and Paige C.J. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 1 (2000) 392-397
59. Page N.M., Bell N.J., Gardiner S.M., et al. Characterisation of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci USA 100 (2003) 6245-6250
60. Khawaja A.M., and Rogers D.F. Tachykinins: receptor to effector. Int J Biochem Cell Biol 28 (1996) 721-738
61. Gudat F., Laubscher A., Otten U., and Pletscher A. Shape changes induced by biologically-active peptides and nerve growth-factor in blood-platelets of rabbits. Br J Pharmacol 74 (1981) 533-538
62. Savi P., Laplace M.C., Lefur G., Emondsalt X., and Herbert J.M. The Nk1 receptor is involved in the neurokinin-induced shape change of rabbit platelets. FEBS Lett 312 (1992) 200-202
63. Gecse A., Kis B., Mezei Z., and Telegdy G. The effect of bradykinin and substance P on the arachidonate cascade of platelets. Immunopharmacology 33 (1996) 167-170
64. Gecse A., Kis B., Mezei Z., and Telegdy G. Effects of inflammatory neuropeptides on the arachidonate cascade of platelets. Int Arch Allergy Immunol 118 (1999) 166-170
65. Kis B., Mezei Z., Gecse A., and Telegdy G. The effect of substance P on the arachidonate cascade of rat platelets. Acta Physiol Hung 85 (1997) 89-97
66. Page N.M., Woods R.J., Gardiner S.M., et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature 405 (2000) 797-800
67. Blum A.M., Metwali A., Cook G., Mathew R.C., Elliott D., and Weinstock J.V. Substance-P modulates antigen-induced, Ifn-gamma production in murine schistosomiasis-Mansoni. J Immunol 151 (1993) 225-233
68. Ho W.Z., Lai J.P., Zhu X.H., Uvaydova M., and Douglas S.D. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 159 (1997) 5654-5660
69. Lai J.P., Douglas S.D., and Ho W.Z. Human lymphocytes express substance P and its receptor. J Neuroimmunol 86 (1998) 80-86
70. Zimmer A., Zimmer A.M., Baffi J., et al. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci USA 95 (1998) 2630-2635
71. Falati S., Gross P.L., Merrill-Skoloff G., et al. In vivo models of platelet function and thrombosis: study of real-time thrombus formation. Methods Mol Biol 272 (2004) 187-197
72. Alvaro G., and Di Fabio R. Neurokinin 1 receptor antagonists-current prospects. Curr Opin Drug Disc Dev 10 (2007) 613-621
73. Duffy R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 9 (2004) 9-21
74. Patel L., and Lindley C. Aprepitant-a novel NK1-receptor antagonist. Exp Opin Pharm 4 (2003) 2279-2296